{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:57:48Z","timestamp":1754161068822,"version":"3.41.2"},"reference-count":29,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Anti-Sj\u00f6gren\u2019s syndrome type A (SSA)-autoantibodies are present in \u00bd-1% of the population and associated with neonatal lupus erythematosus (NLE), of which congenital atrioventricular (AV) block is the most severe manifestation. The aim of this review is to map the road for an anti-SSA-autoantibody-positive woman from wish to conceive until birth, and beyond. With proper care, it is possible to reduce both the risk of NLE and AV-block, and today children born with NLE and AV-block can lead an almost normal life. It is vital that all doctors know of the autoantibody, treatment, and possible outcome.<\/jats:p>","DOI":"10.61409\/v07240457","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T01:52:57Z","timestamp":1740707577000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Anti-Sj\u00f6gren\u2019s syndrome type A-autoantibodies and pregnancy"],"prefix":"10.61409","author":[{"given":"Camilla Lassen","family":"Dreyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Fuglsang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik Kj\u00e6rulf","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Glerup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper Vandborg","family":"Bjerre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bent","family":"Deleuran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Louise N\u00e6stholt","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Kaplinski M, Cuneo BF. Novel approaches to the surveillance and management of fetuses at risk for anti-Ro\/SSA mediated atrioventricular block. Semin Perinatol. 2022;46(4):151585. https:\/\/doi.org\/10.1016\/j.semperi.2022.151585","DOI":"10.1016\/j.semperi.2022.151585"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Diaz T, Dominguez D, Jaeggi E et al. Ethnicity and neonatal lupus erythematosus manifestations risk in a large multiethnic cohort. J Rheumatol. 2021;48(9):1417-1421. https:\/\/doi.org\/10.3899\/jrheum.201338","DOI":"10.3899\/jrheum.201338"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Decker P, Moulinet T, Pontille F et al. An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management. Autoimmun Rev. 2022;21(3):103013. https:\/\/doi.org\/10.1016\/j.autrev.2021.103013","DOI":"10.1016\/j.autrev.2021.103013"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Schneeberger E, Citera G, Heredia M, Cocco JM. Clinical significance of anti-Ro antibodies in rheumatoid arthritis. Clin Rheumatol. 2008;27(4):517-9. https:\/\/doi.org\/10.1007\/s10067-007-0812-x","DOI":"10.1007\/s10067-007-0812-x"},{"key":"ref4","unstructured":"DanskReumatologi.dk. Graviditet, amning og mandlig reproduktion ved autoimmune, reumatologiske sygdomme, 2023. https:\/\/danskreumatologi.dk\/nbv\/sygdomme\/graviditet-amning-og-mandlig-reproduktion-ved-autoimmune-reumatologiske-sygdomme\/ (15. apr 2024)"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Ambrosi A, Wahren-Herlenius M. Congenital heart block: evidence for a pathogenic role of maternal autoantibodies. Arthritis Res Ther. 2012;14(2):208. https:\/\/doi.org\/10.1186\/ar3787","DOI":"10.1186\/ar3787"},{"key":"ref6","unstructured":"Delauran BW, Troldborg AM, Hermansen MLF. Graviditet ved reumatologiske sygdomme, 2021. https:\/\/e-dok.rm.dk\/edokshort\/XC02ED44B4EE7F1ADC12586F5002BA935 (01. apr 2024)"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Pruetz JD, Miller JC, Loeb GE et al. Prenatal diagnosis and management of congenital complete heart block. Birth Defects Res. 2019;111(8):380-388. https:\/\/doi.org\/10.1002\/bdr2.1459","DOI":"10.1002\/bdr2.1459"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Izmirly PM, Costedat-Chalumeau N, Pisoni CN et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA\/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation. 2012;126(1):76-82. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.089268","DOI":"10.1161\/CIRCULATIONAHA.111.089268"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Wainwright B, Bhan R, Trad C et al. Autoimmune-mediated congenital heart block. Best Pract Res Clin Obstet Gynaecol. 2020;64:41-51. https:\/\/doi.org\/10.1016\/j.bpobgyn.2019.09.001","DOI":"10.1016\/j.bpobgyn.2019.09.001"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Brito-Zer\u00f3n P, Izmirly PM, Ramos-Casals M et al. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol. 2015;11(5):301-12. https:\/\/doi.org\/10.1038\/nrrheum.2015.29","DOI":"10.1038\/nrrheum.2015.29"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Liszewska A, Wo\u017aniacka A. Neonatal lupus erythematosus - prevention is better than cure. Postepy Dermatol Alergol. 2022;39(6):1021-1026. https:\/\/doi.org\/10.5114\/ada.2022.122601","DOI":"10.5114\/ada.2022.122601"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Hunter LE, Simpson JM. Atrioventricular block during fetal life. J Saudi Heart Assoc. 2015;27(3):164-78. https:\/\/doi.org\/10.1016\/j.jsha.2014.07.001","DOI":"10.1016\/j.jsha.2014.07.001"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Gryka-Marton M, Szukiewicz D, Teliga-Czajkowska J, Olesinska M. An overview of neonatal lupus with anti-Ro characteristics. Int J Mol Sci. 2021;22(17):9281. https:\/\/doi.org\/10.3390\/ijms22179281","DOI":"10.3390\/ijms22179281"},{"key":"ref14","unstructured":"Diaz-Frias J, Badri T. Neonatal lupus erythematosus, 2023. StatPearls [Internet]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK526061\/ (10. maj 2024)"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr. 2003;142(6):678-83. https:\/\/doi.org\/10.1067\/mpd.2003.233","DOI":"10.1067\/mpd.2003.233"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Lee LA. The clinical spectrum of neonatal lupus. Arch Dermatol Res. 2009;301(1):107-10. https:\/\/doi.org\/10.1007\/s00403-008-0896-4","DOI":"10.1007\/s00403-008-0896-4"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Zuppa AA, Riccardi R, Frezza S et al. Neonatal lupus: Follow-up in infants with anti-SSA\/Ro antibodies and review of the literature. Autoimmun Rev. 2017;16(4):427-432. https:\/\/doi.org\/10.1016\/j.autrev.2017.02.010","DOI":"10.1016\/j.autrev.2017.02.010"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Mawad W, Hornberger L, Cuneo B, Raboisson MJ et al. Outcome of antibody-mediated fetal heart disease with standardized anti-inflammatory transplacental treatment. J Am Heart Assoc. 2022;11(3):e023000. https:\/\/doi.org\/10.1161\/JAHA.121.023000","DOI":"10.1161\/JAHA.121.023000"},{"issue":"2","key":"ref19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/art.22543","article-title":"Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus","volume":"57","author":"Boros","year":"2007","unstructured":"Boros CA et al. Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus. Arthritis Rheum. 2007;57(2):261-6","journal-title":"Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Hon KL, Leung AK. Neonatal lupus erythematosus. Autoimmune Dis. 2012;2012:301274","DOI":"10.1155\/2012\/301274"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Feldkamp ML et al. Etiology and clinical presentation of birth defects: population based study. BMJ. 2017;357:j2249","DOI":"10.1136\/bmj.j2249"},{"issue":"2","key":"ref22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/0961203320973076","article-title":"Systemic lupus erythematosus during pregnancy is not associated with school performance in offspring - a Danish population-based study","volume":"30","author":"Knudsen","year":"2021","unstructured":"Knudsen SS et al. Systemic lupus erythematosus during pregnancy is not associated with school performance in offspring - a Danish population-based study. Lupus. 2021;30(2):228-237","journal-title":"Lupus"},{"key":"ref23","unstructured":"Neonatal Lupus: Management and outcomes; tilg\u00e5et juni 2024; UpToDate; https:\/\/www-uptodate-com.ez.statsbiblioteket.dk\/contents\/neonatal-lupus-management-and-outcomes?search=Neonatal%20lupus&source=search_result&selectedTitle=2%7E36&usage_type=default&display_rank=2"},{"issue":"3","key":"ref24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1159\/000513202","article-title":"Effects of Transplacental Dexamethasone Therapy on Fetal Immune-Mediated Complete Heart Block","volume":"48","author":"Saito","year":"2021","unstructured":"Saito M et al. Effects of Transplacental Dexamethasone Therapy on Fetal Immune-Mediated Complete Heart Block. Fetal Diagn Ther. 2021;48(3):183-188","journal-title":"Fetal Diagn Ther"},{"key":"ref25","unstructured":"Acetylsalicylsyre i graviditeten; Anita Sylvest Andersen; 2022; https:\/\/static1.squarespace.com\/static\/5467abcce4b056d72594db79\/t\/631a45b6ebace45e11ec2273\/1662666169631\/AcetylsalicylsyreGuidelineFinal+.pdf"},{"issue":"1","key":"ref26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","unstructured":"Fanouriakis A et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the Rheumatic Diseases. 2024;83(1):15-29.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"ref27","unstructured":"E-dok, Region Midtjylland; AV-blok - CHB - PR-interval - SSA\/Ro, SSB\/La- antistoffer; https:\/\/e-dok.rm.dk\/edokshort\/X9033DE0B968E530EC1257730003796B2 (01. apr 2024)"},{"issue":"35","key":"ref28","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","article-title":"2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy","volume":"42","author":"Glikson","year":"2021","unstructured":"Glikson M et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427-3520","journal-title":"Eur Heart J"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:31:42Z","timestamp":1753709502000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V07240457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":29,"URL":"https:\/\/doi.org\/10.61409\/v07240457","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2025,2,24]]}}}